What's new? Log in Free sign up

Industry / Biological Product (except Diagnostic) Manufacturing

Trending Companies

Companies in the news

P/E Ratio Insights for Amgen

Gilead Sciences

A Look Into Gilead Sciences Inc's Price Over Earnings

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analyst Targets

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analyst Targets

JP Morgan Maintains Overweight on argenx, Lowers Price Target to $560

BioNTech Has Signed A Multi-year Strategic Partnership With The State Of Victoria In Australia, Building On A Letter Of Intent Agreed On In October 2022

Acceleron Pharma

Expert Ratings for Bio-Techne

Neurocrine Biosciences

Analyst Expectations for Neurocrine Biosciences's Future

Latest filings

All filings

FUSN Fusion Pharmaceuticals

Notice of proposed sale of securities

SABS SAB Biotherapeutics

Preliminary proxy

FRLN Freeline Therapeutics

Going private transaction

Amendments to Articles of Incorporation or Bylaws

TCON TRACON Pharmaceuticals

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

EVAX Evaxion Biotech A/S

Current report (foreign)

Notice of proposed sale of securities (amended)

Notice of proposed sale of securities (amended)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

ADVM Adverum Biotechnologies

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Upcoming Earnings Releases

Earnings calendar

Champions Oncology

PharmaCyte Biotech

Outlook Therapeutics

Gilead Sciences

Neurocrine Biosciences

Latest IPO Filings (S1/F1/S11)

IPO calendar

WINT Windtree Therapeutics

ZIVO Zivo Bioscience

PALI Palisade Bio

TCON TRACON Pharmaceuticals

APTO Aptose Biosciences

TTNP Titan Pharmaceuticals, Inc.

MBOT Microbot Medical

ZIVO Zivo Bioscience

SCNI Scinai Immunotherapeutics

APTO Aptose Biosciences

Stock splits Upcoming and recent stock splits

Splits calendar

Harpoon Therapeutics

Harpoon Therapeutics

PHAXIAM Therapeutics

Zivo Bioscience

News

From Benzinga Pro

Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML

Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting

Harpoon Therapeutics, Inc. Files Prospectus For The Offering and Resale Of 25,751,025 Shares Of Common Stock By Selling Stockholders

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder

Moderna's Options Frenzy: What You Need to Know

Bluebird Bio Details Plans For The Commercial Launch Of LYFGENIA Gene Therapy For Patients Ages 12 And Older With Sickle Cell Disease And A History Of Vaso-Occlusive Events; Bluebird Has Set Wholesale Acquisition Cost Of LYFGENIA In U.S. At $3.1M

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Truist Securities Reiterates Buy on CRISPR Therapeutics, Maintains $220 Price Target

Vertex And CRISPR Therapeutics Announce U.S. FDA Approval Of CASGEVY For The Treatment Of Sickle Cell Disease

Mizuho Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Press releases

From Benzinga Pro

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

BRAINSTORM DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options

OUTLOOK ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Community annotations

(No comment added)

Community notes

MILESTONE OF 1,000 U.S. PATIENTS ON ORLADEYO SURPASSED

HAE market - 2021 vs 2022

Orladeyo sales in Japan -- Q1/2023 --TORII Partner

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Patents

Pyrrole Compounds

Sustained Release Aminopyridine Composition

Treatment of HER2 Positive Cancers

Method of Treatment of Cancer or Tumour

Engineered Ipsc and Persistent Immune Effector Cells

Fusobacterium Bacteriophage and Uses Thereof

Multiplex Gene Edited Cells for CD70-DIRECTED Cancer Immunotherapy

Vectorized Factor XII Antibodies and Administration Thereof

Dihydroquinazolinones and Related Analogs for Inhibiting Yap/taz-tead

GLP-1R Modulating Compounds

Reddit threads

Daily Discussion Thread - December 8th, 2023

Daily Plays December 07, 2023

They printed $10 Trillion dollars, gave you a $1,400 stimulus check, gave the wealthy PPP loans that were forgiven, then left you with the inflation, higher costs of living and an 8% mortgage rate. Brilliant for a the rich, painful for you?

fluentinfinance

About a month ago I started investing, and a week ago I thought I’d try my hand at penny stocks. Goin pretty well so far!

List of December's FDA/PDUFA catalyst and their Options sentiments

Daily Discussion Thread - December 5th, 2023

Daily Discussion Thread - December 4th, 2023

$CBIA Canopus Biopharma, Inc. DD Overview

Is anything really a "forever stock?"

Daily Plays December 02, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.